Search results
Results from the WOW.Com Content Network
Over the counter expectorants (like Mucinex) or a decongestant (like Sudafed) can help with your chest congestion, says Dr. Watkins. Decongestants and expectorants are both effective at treating ...
Pseudoephedrine is contraindicated in patients with diabetes mellitus, cardiovascular disease, severe or uncontrolled hypertension, severe coronary artery disease, prostatic hypertrophy, hyperthyroidism, closed-angle glaucoma, or by pregnant women. [56] The safety and effectiveness of nasal decongestant use in children is unclear. [57]
The FDA says that children under two should not be given any type of cold and flu that contains a decongestant or an antihistamine because of dangerous side effects. For children ages two to four ...
The FDA announced a proposal to remove oral phenylephrine, found in many popular OTC decongestants, from shelves. The reason for the ban is that the ingredient just isn’t effective, the FDA says.
A decongestant, or nasal decongestant, is a type of pharmaceutical drug that is used to relieve nasal congestion in the upper respiratory tract. The active ingredient in most decongestants is either pseudoephedrine or phenylephrine (the latter of which has disputed effectiveness ).
Naphazoline is a medicine used as a decongestant, and a vasoconstrictor added to eye drops to relieve red eye. It has a rapid action in reducing swelling when applied to mucous membranes . It is a sympathomimetic agent with marked alpha adrenergic activity that acts on alpha-receptors in the arterioles of the conjunctiva to produce constriction ...
The drug became the main ingredient in OTC decongestants after medicines with pseudoephedrine were moved behind the pharmacy counter due to the Combat Methamphetamine Epidemic Act of 2005, which ...
Xylometazoline is in the decongestant and alpha-adrenergic agonist families of medication. [5] [6] One study classified it with selectivity ratios in alpha 2 adrenergic receptors of 151 for a2A vs a2B, 4.5 a2A vs a2C, and 33.9 a2B vs a2C. Making it a highly selective a2A agonist. [7] Xylometazoline was patented in 1956 and came into medical use ...